Skip to main content
. 2022 Mar 22;46:101354. doi: 10.1016/j.eclinm.2022.101354

Table 9.

Average cost estimate for glaucoma and diabetic retinopathy treatment. Costs are in 2018 USD purchasing power parity.

Country Reference Cause Treatment Sample size Year of cost data Unit of Observation Perspective of analysis in 2018 USD ppp
Quality appraisal score
Direct costs
Productivity Losses Informal Care costs
Medical (1) Non- medical (2) Total (1) + (2)
Western Europe
 Finland 126 Glaucoma All types a 168 2006 Patient Health System 1354 9
 4 EU
countries b
61 Glaucoma Unspecified 162 2005 Patient Health System
and Societal
1238 4034 5272 8
High Income North America
 United States 127 Glaucoma All types a 81 N.R Patient Payer 1476; 2664 c 8
 United States 62 Glaucoma Surgical N.R 2013 Episode Health System 8555 d; 6707;
10,949

-
10
 United States 59 Diabetic
Retinopathy
Anti-VEGF 213 2018 Episode Health System 40,825 e 8
 United States 128 Diabetic
Retinopathy
Unspecified 1441 2012 Patient Payer 17,280 f 2210 5.5
Western sub-Saharan Africa
 Nigeria 60 Glaucoma Surgical 120 2006 Patient Patient and
Governmental
878 8
Tropical Latin America
 Brazil 129 Glaucoma Surgical 227 2010 Surgery Health System 351;415;448g 7

USD – United States Dollars ($); ppp- purchasing power parity; EU – European; N.R – Not reported.

a

It includes surgical, laser and medical treatment available in the country.

b

France, Denmark, Germany and the United Kingdom.

c

Average cost for second year of treatment (lowest value) and first year of treatment (highest costs);.

d

Average cost of trabeculectomy treatment over 5 years ($8555 ppp), mean cost for medical treatment in the same time period was reported as$ 6707 ppp and for tube insertion as $10,949 ppp;.

e

Average cost for a 5 year period for patients with proliferative diabetic retinopathy and center involved diabetic macular edema treated with ranibizumab.

f

Average cost for diabetic retinopathy Non- drivers cohort. Commercial driver cohort data was not reported since it included exclusively persons for whom good vision is required to maintain employment.

g

Average direct costs of non-penetrating deep sclerectomy by glaucoma severity level: early / moderate/ severe.